Möchten Sie immer auf dem neuesten Stand bleiben?

Aicuris today announced positive results from its pivotal Phase 3 trial evaluating pritelivir in immunocompromised patients with refractory HSV

Wuppertal, Germany, January 29, 2026 - Aicuris Anti-infective Cures AG (“Aicuris”) today announced that the company will be presenting the results of pritelivir from their pivotal Phase 3 trial...

Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "STD Diagnostics Market Report by Test Type, Technology, Location of Testing, End User, Countries and Company Analysis, 2025-2033" has been added to ...

Results from pritelivir Phase 2 study demonstrate a favorable safety profile and a numerically higher lesion healing rate vs. foscarnetPritelivir Phase 2 results supported FDA Breakthrough Therapy...

Pritelivir demonstrated clinically meaningful and highly statistically significant superiority (p=0.0047) in lesion healing up to 28 days of treatment, compared with standard-of-care (SoC) treatments...

Company will provide an overview of the pritelivir clinical development program in two oral presentations including a comprehensive Phase 2 data overviewUpdated safety and pharmacokinetic results of...

Initial results from the First in Human (FIH) Phase 1 trial evaluating AIC468, a 2nd generation antisense oligonucleotide (ASO), in healthy volunteers demonstrated favorable pharmacokinetic (PK)...

Wuppertal, Germany, July 24, 2025 - Aicuris Anti-infective Cures AG today announced the completion of patient enrollment in its pivotal Phase 3 trial, PRIOH-1, evaluating pritelivir for the treatment...

Dublin, June 17, 2025 (GLOBE NEWSWIRE) -- The "Sexually Transmitted Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade,...

Wilmington, Delaware, United States, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global oncolytic virus immunotherapy market was projected to attain US$ 110.2 million...